Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R,R)-penehyclidine fumarate is a potent, long-acting anticholinergic agent and the most pharmacologically active stereoisomer of penehyclidine. Developed by the Institute of Toxicology and Pharmacology at the Academy of Military Medical Sciences in China, it functions as a selective antagonist of M1 and M3 muscarinic receptors and nicotinic receptors, while exhibiting significantly lower affinity for M2 receptors. This selectivity profile is designed to provide effective inhibition of glandular secretions and smooth muscle relaxation without the significant tachycardia often induced by non-selective anticholinergics like atropine. It is primarily utilized as a pre-anesthetic medication to inhibit secretions and as a treatment for organophosphate nerve agent poisoning.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (R,R)-penehyclidine fumarate.